Dyne Therapeutics (NASDAQ:DYN) Given Buy Rating at Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of Dyne Therapeutics (NASDAQ:DYN) in a research note published on Friday,Benzinga reports. Chardan Capital currently has a $50.00 price objective on the stock.

Several other equities analysts have also weighed in on the company. JPMorgan Chase & Co. lowered Dyne Therapeutics from an “overweight” rating to a “neutral” rating and cut their target price for the company from $43.00 to $35.00 in a report on Thursday, October 24th. HC Wainwright restated a “buy” rating and set a $55.00 target price on shares of Dyne Therapeutics in a report on Friday. Raymond James upgraded Dyne Therapeutics to a “strong-buy” rating in a report on Thursday, December 12th. Robert W. Baird began coverage on Dyne Therapeutics in a report on Friday, December 13th. They set an “outperform” rating and a $46.00 target price on the stock. Finally, Baird R W upgraded Dyne Therapeutics to a “strong-buy” rating in a report on Thursday, December 12th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, ten have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Dyne Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $49.91.

Dyne Therapeutics Trading Down 31.1 %

Shares of NASDAQ:DYN opened at $15.87 on Friday. Dyne Therapeutics has a 1 year low of $14.79 and a 1 year high of $47.45. The business has a fifty day simple moving average of $27.29 and a 200 day simple moving average of $34.15. The firm has a market cap of $1.62 billion, a price-to-earnings ratio of -4.46 and a beta of 1.16.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.25). On average, sell-side analysts forecast that Dyne Therapeutics will post -3.44 EPS for the current year.

Insider Activity

In related news, Director Dirk Kersten sold 23,671 shares of Dyne Therapeutics stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $35.35, for a total transaction of $836,769.85. Following the sale, the director now directly owns 99,652 shares of the company’s stock, valued at $3,522,698.20. This trade represents a 19.19 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Carlo Incerti sold 16,500 shares of Dyne Therapeutics stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $28.73, for a total value of $474,045.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 44,742 shares of company stock valued at $1,443,246. 20.77% of the stock is owned by insiders.

Institutional Investors Weigh In On Dyne Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC boosted its holdings in Dyne Therapeutics by 4.3% during the second quarter. AQR Capital Management LLC now owns 8,495 shares of the company’s stock valued at $300,000 after purchasing an additional 352 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Dyne Therapeutics by 24.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,631 shares of the company’s stock valued at $123,000 after purchasing an additional 709 shares in the last quarter. KBC Group NV boosted its holdings in Dyne Therapeutics by 53.4% during the third quarter. KBC Group NV now owns 2,157 shares of the company’s stock valued at $77,000 after purchasing an additional 751 shares in the last quarter. Amalgamated Bank raised its stake in shares of Dyne Therapeutics by 39.9% in the second quarter. Amalgamated Bank now owns 2,792 shares of the company’s stock valued at $99,000 after acquiring an additional 796 shares during the last quarter. Finally, Quantbot Technologies LP bought a new position in shares of Dyne Therapeutics in the third quarter valued at approximately $34,000. 96.68% of the stock is owned by institutional investors and hedge funds.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.